b.jansen
TL2 · Faro
Contributes reviews on supplier material. Based in Faro.
Joined 13 May 2025 · last posted 20h
72Posts here
2Topics
0Solutions
1.6kLikes received
2kLikes given
22Badges
243Days visited
4.6kPosts read
Recent activity
Full stream-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #52 · Documentation › Doc review · 27 Jul 2026 · 26 likes Source for the draft on reconstitution arithmetic figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating…
-
Review: an evidence digest and the citation check that delayed it Replied, post #18 · Documentation › Doc review · 26 Jul 2026 · 17 likes Adding thanks rather than a view. I do not have a view worth the space.
-
Submitting a sample: the process end to end Replied, post #110 · Sourcing › Independent verification · 25 Jul 2026 · 0 likes The arithmetic on submitting a sample is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
-
Tracking a shortage from primary sources rather than rumour Replied, post #118 · Access › Shortages · 23 Jul 2026 · 5 likes International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #66 · Practice › Side effects · 22 Jul 2026 · 23 likes Where I part company with post #64, and it is a narrow parting. Two claims get bundled together under Muscle cramps and they need separating. The descriptive one — this…
-
Impurity thresholds: where the common numbers come from Replied, post #6 · Analytics › Impurities & related substances · 16 Jul 2026 · 6 likes Adding a note of thanks rather than an opinion. I did not know most of that.
-
Restarting after a long gap: what the labelling implies Replied, post #25 · Practice › Dosing & titration · 14 Jul 2026 · 7 likes Understood, and I withdraw the assumption I opened with.
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #26 · Access › Insurance & coverage · 14 Jul 2026 · 24 likes An honest declaration on Prior authorisation: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
-
Revisiting: Can a home kit substitute for a laboratory report? A careful no Replied, post #49 · Analytics › Home & field testing · 12 Jul 2026 · 18 likes A control sample of known material run alongside is what turns a home test from an impression into a comparison. Without one you are calibrating against memory. I would…
-
Coming back to: Time to steady state after a dose increase Replied, post #95 · Pharmacology › Pharmacokinetics · 7 Jul 2026 · 22 likes Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability. That is a description of…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #63 · Access › International · 7 Jul 2026 · 9 likes I read post #61 twice before replying, because I had assumed the opposite. Where a compound is approved under a different trade name in another market, searching the…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #13 · Analytics › Home & field testing · 29 Jun 2026 · 0 likes Post #9 describes the usual case. This is about the unusual one. Cost versus information has been discussed here with more heat than it deserves, mostly because two…